Darmstadt, Germany, June 17, 2014 – Merck KGaA, Darmstadt, Germany, announced today that it has reached a mutual agreement with Ono Pharmaceutical Co., Ltd., Osaka, Japan, to terminate the license agreement on ceralifimod (ONO-4641) because it does not meet the company’s threshold for continued investment. Merck KGaA, Darmstadt, Germany, obtained worldwide exclusive license rights from Ono Pharmaceutical for the development and commercialization of ceralifimod (ONO-4641) in multiple sclerosis (MS) outside of Japan, Korea and Taiwan in October 2011. The drug candidate is currently in clinical development (Phase II).

The biopharmaceutical division of Merck KGaA, Darmstadt, Germany, remains committed to improving the lives of people with MS, and will continue to pursue external collaborations and internal development programs aimed at identifying and developing high quality candidate molecules with the goal of making a real difference in the lives of people with MS.

About multiple sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million patients have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.